Screen LibraryMolecular diagnostics in cancer patients /
Saved in:
| Group Author: | ; ; |
|---|---|
| Published: |
Springer,
|
| Publisher Address: | Singapore : |
| Publication Dates: | [2019] |
| Literature type: | Book |
| Language: | English |
| Subjects: | |
| Carrier Form: | viii, 341 pages : illustrations (chiefly color) ; 27 cm |
| Bibliography: | Includes bibliographical references. |
| ISBN: |
9789811358760 9811358761 |
| Index Number: | RB43 |
| CLC: |
R730.4 R446.1 |
| Call Number: | R446.1/M718-1 |
| Contents: |
Intro; Contents; About the Editors; 1: Recent Advances in Molecular Diagnostic Approaches for Cancer; 1.1 Introduction; 1.2 Causes of Cancer; 1.3 Classification of Cancers; 1.4 Screening of Cancer; 1.5 Diagnosis; 1.6 Molecular Biomarkers; 1.7 Various Techniques Used in Molecular Diagnostics; 1.7.1 Polymerase Chain Reaction (PCR); 1.7.2 Real-Time PCR; 1.7.3 DNA Sequencing; 1.7.4 Microarrays; 1.7.5 Cytogenetic Testing; 1.7.6 Fluorescent In Situ Hybridization (FISH); 1.7.7 Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS); 1.8 Prognosis 1.9 Pharmacokinetics and Pharmacodynamics1.10 Conclusion; References; 2: Molecular Diagnosis of Gall Bladder Cancer; 2.1 Gallbladder Cancer; 2.2 Risk Factors GBC; 2.2.1 Age, Gender, Race and Socioeconomic Status; 2.2.2 Gallstone and Other Pre-existing Diseases; 2.2.3 Chronic Inflammation; 2.2.4 Infections; 2.2.5 Diet; 2.2.6 Obesity; 2.2.7 Genetic Susceptibility and Family History; 2.3 Pathogenesis of Gallbladder Cancer; 2.4 GBC Types; 2.5 Clinical Presentation; 2.6 Diagnostic Methods; 2.6.1 Blood test/Serum Markers; 2.6.2 Imaging Techniques; 2.6.3 Elastography 2.6.4 PET and PET/CT2.6.5 Endoscopic retrograde cholangiopancreatography (ERCP/ERC); 2.6.6 Percutaneous Transhepatic Cholangiography (PTC); 2.6.7 Biopsy; 2.7 Molecular Markers for GBC Diagnosis and Prognosis; 2.8 Conclusion; References; 3: Molecular Diagnostics for Lung Cancer; 3.1 Introduction; 3.2 Classification of Lung Cancer; 3.3 Genetic Aberrations in Lung Cancer; 3.3.1 Epidermal Growth Factor Receptor (EGFR); 3.3.2 Anaplastic Lymphoma Kinase (ALK); 3.3.3 ROS1 (c-Ros Oncogene 1); 3.3.4 RET (Rearranged During Transfection); 3.3.5 MET 3.3.6 KRAS (Kirsten Rat Sarcoma Viral Oncogene Homologue)3.3.7 PI3K (Phosphatidylinositol- 3-Kinase); 3.4 Various Techniques Used in Molecular Diagnostics; 3.4.1 Fluorescent In Situ Hybridization (FISH); 3.4.2 Immunohistochemistry (IHC); 3.4.3 Sanger Sequencing; 3.4.4 Allele-Specific PCR and Real-Time PCR; 3.5 Emerging Technologies for Molecular Diagnostics; 3.5.1 High-Throughput Multiplexing Assays; 3.5.2 Next Generation Sequencing (NGS); 3.5.3 Liquid Biopsy; 3.6 Challenges; 3.7 Quality Control for Molecular Pathology Testing for Lung Cancer; 3.7.1 Pre-analytical 3.7.2 AnalyticalReferences; 4: Predicting E3 Ubiquitin Ligases as Possible Promising Biomarkers for Brain Tumors; 4.1 Introduction; 4.2 What Are Biomarkers and How Are They Helpful in the Early Diagnosis of Tumors?; 4.2.1 Prognostic Biomarkers; 4.2.2 Predictive Biomarkers; 4.2.3 Pharmacodynamic Biomarkers; 4.3 Methods, Tools and Challenges Associate with Biomarker Detection Approaches; 4.3.1 Gene Analysis; 4.3.2 Proteome Analysis; 4.3.3 Metabolite Analysis; 4.4 The Protein Quality Control Mechanism and Its Association with Cancers; 4.4.1 Autophagy |